Clinical studies suggest that mTOR inhibitors reduce the risk of cancer following organ transplant, which may be linked to inhibition of the mTOR pathway (Akt/PI3K) and blocking of mRNA translation of some procarcinogenic factors, such as VEGF, cyclin D1, and IL-10 [51]. This evidence concerns the gene MTOR and cancer.